Findings on Hidradenitis Suppurativa Detailed by Investigators at St. Vincent's University Hospital (Treatment of Hidradenitis Suppurativa With Adalimumab In the Pioneer I and Ii Randomized Controlled Trials Reduced Indices of Systemic...).

Researchers at St. Vincent's University Hospital in Dublin, Ireland, conducted a study on Hidradenitis Suppurativa (HS) and its association with cardiovascular disease (CVD) risk. The study focused on biomarkers of systemic inflammation and CVD, such as the systemic immune inflammation index (SII), neutrophil/lymphocyte (NLR), platelet/lymphocyte (PLR), and monocyte/lymphocyte ratios (MLR). The findings indicated that treatment with adalimumab resulted in a rapid and sustained reduction in systemic inflammation, which correlated with CVD risk. The research concluded that SII, NLR, and PLR may predict the response to adalimumab treatment, depending on their interaction with the number of draining fistulae. [Extracted from the article]